

**AACR 2025 Annual Meeting: Ludwig Community Presentation Sessions**

Session date	Session title	Session type	Presentation title	Ludwig location	Scientist name	Session time (U.S. CST)
4/25/2025	Multimodal Spatiotemporal Mapping of Cell States, Organization, and Interactions	Educational Session	High-resolution and noninvasive profiling of the tumor microenvironment with spatial ecotypes	Ludwig Stanford	Aaron Newman	3:30 PM
4/25/2025	Drug Repurposing in Oncology: Opportunities and Challenges	Educational Session	Repurposing drugs to overcome PARP inhibitor resistance	Ludwig Harvard	Alan D'Andrea	5:15 PM
4/26/2025	The Evolution of Cancer Hallmarks: Insights and Moving Forward	Educational Session	Circadian clock disruption: A hallmark of cancer.	Ludwig Institute	Chi Van Dang	8:30 AM
4/26/2025	Tumor Metabolism and the Tumor Microenvironment	Educational Session	Chairperson/Chair Introduction/What is there to eat around here? How metabolic constraints in the tumor microenvironment impact cancer biology	Ludwig Chicago	Alexander Muir	10:00 AM
4/26/2025	Myeloid Cell Biology in the Tumor Microenvironment and Reprogramming Myeloid Cells to Enhance Anti-tumor Immune Responses	Educational Session	Unraveling the complexities of tumor associated macrophages for anti-cancer therapy	Ludwig Harvard	Jennifer Guerriero	1:00 PM
4/26/2025	Ex Vivo Models of the TME	Educational Session	Chairperson/Chair Introduction/Title to be announced	Ludwig Stanford	Calvin Kuo	2:30 PM
4/26/2025	Artificial Intelligence in Cancer Immunology	Educational Session	Chairperson/Chair Introduction/Data science, machine learning, and artificial intelligence in cancer immunology	Ludwig Harvard	Franziska Michor	2:30 PM
4/26/2025	Ex Vivo Models of the TME	Educational Session	High resolution dynamic ex vivo profiling of the immune TME	Ludwig Harvard	David Barbie	3:00 PM
4/26/2025	Discovery Science Plenary: Novel Mechanisms Influencing Cancer Evolution	Plenary Session	Simultaneous perturbation of epigenetic and signaling pathways rewires transcription and synergistically induce AML differentiation	Ludwig Oxford	Yang Shi	5:14 PM
4/27/2025	Opening Plenary: Unifying Cancer Science and Medicine—A Continuum of Innovation for Impact	Plenary Session	Chairperson/Introduction	Ludwig MIT	Matthew Vander Heiden	9:30 AM
4/27/2025	Opening Plenary: Unifying Cancer Science and Medicine—A Continuum of Innovation for Impact	Plenary Session	Unraveling the complexity of cancer ecosystems	Ludwig Lausanne	Johanna Joyce	10:34 AM
4/27/2025	Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research	Awards and Lectures	Illuminating and reprogramming the immuno-evasive tumor microenvironment to enable immunotherapy	Ludwig Lausanne	Douglas Hanahan	12:10 PM
4/27/2025	Advances in Immunotherapy	Clinical Trials Plenary Session	Discussant	Ludwig Stanford	Maximilian Diehn	1:45 PM
4/27/2025	The Neuroscience of Cancer	Major Symposium	Chairperson/Introduction/Neuronal regulation of brain cancers	Ludwig Stanford	Michelle Monje	1:00 PM
4/27/2025	AACR-Bayard D. Clarkson Symposium: Cellular Plasticity and Heterogeneity in Cancer Progression and Resistance	Major Symposium	Intra- and inter-tumoral heterogeneity in small-cell lung cancer progression and metastasis	Ludwig Stanford	Julien Sage	1:05 PM
4/27/2025	Dharma Master Jiantai Advances in Lung Cancer Research Session: Aging and Environmental Cues Drive Lung Cancer Development and Spread	Advances in Organ Site Research	The role of metabolites in aging, immunity, and cancer	Ludwig Harvard	Marcia Haigis	1:24 PM

4/27/2025	ecDNA Amplifications and Genomic Rearrangements: Drivers, Pathology and Therapeutic Opportunities	Major Symposium	Cancer genes beyond chromosomes	Ludwig Stanford	Howard Chang	1:30 PM
4/27/2025	AACR Award for Lifetime Achievement in Cancer Research	Awards and Lectures	Chair Remarks	Ludwig Harvard	Kornelia Polyak	3:00 PM
4/27/2025	AACR Award for Lifetime Achievement in Cancer Research	Awards and Lectures	Normalizing the tumor microenvironment to improve cancer treatment: Bench to bedside and back	Ludwig Harvard	Rakesh Jain	3:05 PM
4/27/2025	Overcoming Tumor Immune Suppression	Minisymposium	An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer	Ludwig Harvard	Kenichi Shimada (Guerriero Lab)	3:05 PM
4/27/2025	Late-Breaking Research	Minisymposium	T cell targeted lentiviral gene delivery using the PACK-IT Platform generates CAR-T cells with superior potency compared to conventional lentivirus and enables in vivo generation of CD19-CAR T cells capable of controlling leukemia in preclinical models	Ludwig Stanford	Kylie Burdsall (Mackall Lab)	3:50 PM
4/27/2025	Late-Breaking Research	Minisymposium	Circadian misalignment between cancer cells and immune cells drives immune escape	Ludwig Harvard	Chuqian Liang (Brown Lab)	4:20 PM
4/27/2025	AACR-Princess Takamatsu Memorial Lectureship	Awards and Lectures	Chair Remarks	Ludwig MIT	Tyler Jacks	4:30 PM
4/27/2025	Acquired Resistance to Immunotherapies: A Cancer Immunology Working Group Town Hall and Networking Meeting	Town Meeting	*Invited Speaker*	Ludwig Harvard	Judith Agudo	7:10 PM
4/28/2025	Meet the Editors-in-Chief of Cancer Immunology Research: Robert D. Schreiber, PhD and Philip D. Greenberg, MD	Meet and Greet	Engage in informal discussion with the Editors-in-Chief of Cancer Immunology Research, Robert D. Schreiber, PhD and Philip D. Greenberg, MD, about the scope of the journal and types of research manuscripts they are seeking to publish.	Ludwig Institute	Philip Greenberg, Robert Schreiber	10:30 AM
4/28/2025	AACR Annual Business Meeting of Members	Special Session	AACR Past President	Ludwig Institute	Philip Greenberg	12:30 PM
4/28/2025	Understanding Organ-tropic Metastasis	Major Symposium	Chairperson/Introduction/Unraveling the metastatic niche: Mechanisms and systemic complications	Ludwig Princeton	Yibin Kang	12:30 PM
4/28/2025	Overcoming the Tumor Suppressive Role of the Innate Immune System within the Tumor Microenvironment	Major Symposium	Harnessing neutrophil to overcome resistance to immune based therapies.	Ludwig Weill Cornell	Taha Merghoub	12:35 PM
4/28/2025	Application of Systems Biology, Functional Clinical Proteomics and Multi-Omic Approaches for Precision Oncology at the Bedside	Major Symposium	Using multiplexed spatial methods to study primary cancers and develop biomarkers of high-risk tumors	Ludwig Harvard	Peter Sorger	12:35 PM
4/28/2025	Immunometabolism and Metabolic Fitness in Tumors	Major Symposium	Reprogramming the tumor microenvironment with a single punch- our journey from bench to bedside	Ludwig Lausanne	Ping-Chih Ho	1:15 PM
4/28/2025	Innovative Approaches in Drug Discovery: Novel Leads, Degraders, and AI-Driven Solutions	Minisymposium	Development of potent orally bioavailable inhibitors of nicotinamide N-methyl transferase	Ludwig Chicago	Janna Heide (Lengyel Lab)	2:50 PM
4/28/2025	Metabolic Frontiers in Cancer: Amino Acids, Nutrient Dependencies, and Therapeutic Opportunities	Minisymposium	Physiological nutrient levels reveal nucleotide salvage as a dependency in B-cell acute lymphoblastic leukemia	Ludwig MIT	Ryan Elbashir (Vander Heiden Lab)	3:05 PM
4/28/2025	Innovations in Immunotherapy	Minisymposium	Combined silencing of MED12 and activation of IL2 by epigenetic editing enhances CAR T antitumor potency	Ludwig Stanford	Frank Lin (Mackall Lab)	3:05 PM

4/28/2025	Liquid Biopsy: Circulating Nucleic Acids	Minisymposium	Urine cell-free RNA analysis for bladder cancer detection and monitoring	Ludwig Stanford	Kevin Liu (Diehn Lab)	3:20 PM
4/28/2025	Intra-tumor Heterogeneity of Cancer Models: Towards More Realistic Models for Therapy	Forum	Preclinical models of heterogenous breast cancer	Ludwig Harvard	Kornelia Polyak	5:20 PM
4/28/2025	AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research	Awards and Lectures	Metabolic control of cancer progression	Ludwig Institute	Karen Vousden	5:35 PM
4/28/2025	Advances in Tumor-infiltrating Lymphocyte (TIL) and CAR T Therapies	Forum	Unveiling the mechanisms of TIL therapy: Toward next-generation Add to My Itinerary	Ludwig Lausanne	Alexandre Harari	5:40 PM
4/29/2025	Biologics and T-cell Engagers	Clinical Trials Plenary Session	Cochairs	Ludwig Stanford, Ludwig Weill Cornell	Crystal Mackall, Jedd Wolchok	10:15 AM
4/29/2025	Epigenetics and RNA Modification in Hematologic Malignancies	Advances in Hematologic Malignancies	Chromatin regulation by RNA methylation in leukemia	Ludwig Chicago	Chuan He	10:15 AM
4/29/2025	Opportunities in Cancer Early Detection Using Next Generation Liquid Biopsies	Advances in Early Detection and Interception	Chairperson, Chair Remarks, Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection	Ludwig Institute	Victor Velculescu	10:15 AM
4/29/2025	Reality Check: AI in Drug Discovery	Advances in Technologies	Title to be Announced	Ludwig Harvard	Chris Sander	10:17 AM
4/29/2025	The Influence of Diet and Metabolism on Cancer Cell State	Major Symposium	A role for ROS in pancreas cancer progression	Ludwig Institute	Karen Vousden	10:45 AM
4/29/2025	Meet the Editors-in-Chief of Cancer Prevention Research: Raymond N. DuBois, MD, PhD and Nickolas Papadopoulos, PhD	Meet and Greet	Engage in informal discussion with the Editors-in-Chief of Cancer Prevention Research, Raymond N. DuBois, MD and Nickolas Papadopoulos, PhD, about the scope of the journal and types of research manuscripts they are seeking to publish	Ludwig Baltimore	Nickolas Papadopoulos	12:00 PM
4/29/2025	Technical and Clinical Advances in Circulating Tumor DNA Minimal Residual Disease Detection	Major Symposium	Chairperson/Introduction/Advances in ctDNA MRD analysis for early stage cancers	Ludwig Stanford	Maximilian Diehn	12:30 PM
4/29/2025	Checkpoints and Modulators of Tumor Microenvironment	Minisymposium	Cochairperson/Introduction	Ludwig Chicago	Thomas Gajewski	2:30 PM
4/29/2025	Hot Topics in Cancer Prevention: Development of Multi-Cancer Early Detection Tests, Assessment of the Immune Environment, Targets for Cancer Prevention, and Cancer Interception Trials	Minisymposium	Cochairperson/Closing Remarks	Ludwig Stanford	Maximilian Diehn	2:30 PM
4/29/2025	Multi-omic Integration for Cancer Evolution and Therapy	Minisymposium	Defining spatial molecular residual disease by personalized tumor tissue profiling	Ludwig Stanford	Julia Ransohoff (Alizadeh Lab)	3:05 PM
4/29/2025	Adoptive Cell Therapies	Minisymposium	Harnessing the conditional proteolytic activity of ADAM17 to generate autonomous regulatory mechanisms in CAR T cells	Ludwig Stanford	Jeremy Bjelajac (Mackall Lab)	3:05 PM
4/29/2025	AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology	Awards and Lectures	CAR T Cells for Cancer Therapy	Ludwig Stanford	Crystal Mackall	3:10 PM
4/30/2025	AACR Annual Meeting 2025 Highlights: Vision for the Future	Plenary Session	Chairperson/Chair Introduction	Ludwig MIT	Matthew Vander Heiden	12:10 PM

**AACR 2025 Annual Meeting: Ludwig Community Poster Sessions**

Poster session date		Session type - Location	Poster title	Ludwig location	Presenter/Ludwig PI	Session time (U.S. EDT)
4/27/2025	Where's Waldo: Spatial Complexity of the Tumor Microenvironment 1	Section 7	Spatial heterogeneity of tumor cell states in primary cutaneous melanoma	Ludwig Harvard	Tuulia Vallius/Peter Sorger	Evening Session 2-5 PM
4/27/2025	Comprehensive Multiomic Profiling of Chromatin Dynamics, DNA Methylation, and Tumor Microenvironments	Section 9	Epigenomic dissection of histology-specific drivers of testicular germ cell tumors	Ludwig Harvard	Esmé Wheeler/Myles Brown	Evening Session 2-5 PM
4/27/2025	Late-Breaking Research: Tumor Biology 1	Late-Breaking Poster Session - Section 53	Decoding systemic circadian regulation across multi-tissues in response to tumor stress	Ludwig Harvard	Chuqian Liang/Myles Brown	Evening Session 2-5 PM
4/27/2025	Drug Resistance in Molecular Targeted Therapies 1	Section 19	Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by replication stress-induced genomic instability and mitotic cell death	Ludwig Harvard	Chendi Li/Aaron Hata	Evening Session 2-5 PM
4/27/2025	Combination Immunotherapies	Section 28	Targeting TET3 potentiates an effective anti-tumor immune response after irradiation	Ludwig Chicago	Sera Averbek/Stephen Kron	Evening Session 2-5 PM
4/27/2025	Spatial Proteomics and Transcriptomics 1	Section 32	Spatial transcriptomic characterization of uterine carcinosarcomas identifies MECOM as a tumor regulator	Ludwig Chicago	Katherine Kurnit/Ernst Lengyel	Evening Session 2-5 PM
4/27/2025	Imaging in Animal Models	Section 3	Real time imaging of the non-small cell lung cancer immune microenvironment modulation by low dose photodynamic therapy	Ludwig Lausanne	Damien Marie/Johanna Joyce	Evening Session 2-5 PM
4/27/2025	Stem Cells, Development, and Cancer	Section 5	Decoding developmental programs driving tumorigenesis and immunotherapy resistance in triple-negative breast cancer	Ludwig Stanford	Rachel Gleyzer/Aaron Newman	Evening Session 2-5 PM
4/27/2025	Where's Waldo: Spatial Complexity of the Tumor Microenvironment 1	Section 7	High-resolution profiling of the tumor microenvironment with spatial ecotypes	Ludwig Stanford	Wubing Zhang/Aaron Newman	Evening Session 2-5 PM
4/28/2025	Application of Bioinformatics to Cancer Biology	Section 44	Improved non-invasive gene expression inference using advanced machine learning	Ludwig Stanford	Amirsaman Ashtari/Ash Alizadeh	Morning Session 9 AM - 12 PM

4/28/2025	Liquid Biopsy: Circulating Nucleic Acids 5 / Circulating Tumor Cells 2	Section 28	Enhanced detection of pancreatic cancer through methylation-based liquid biopsy: insights into tumor heterogeneity, early alterations, and stromal contributions	Ludwig Stanford	Rui Wang/Ash Alizadeh	Morning Session 9 AM - 12 PM
4/28/2025	Metabolic Dependencies	Section 14	Targeting oxygen consumption with metformin and phenformin have differential effects on immune cells in the tumor microenvironment	Ludwig Weill Cornell	Sadna Budhu/Jedd Wolchok, Taha Merghoub	Morning Session 9 AM - 12 PM
4/28/2025	Digital Pathology	Section 46	Advancing multimodal machine learning techniques to predict platinum resistance in high-grade serous ovarian cancer	Ludwig Chicago	Leonhard Donle/Ernst Lengyel	Morning Session 9 AM - 12 PM
4/28/2025	Digital Pathology	Section 46	Using digital pathology to differentiate survival phenotypes in high-grade serous ovarian cancer	Ludwig Chicago	Kelsey Goon/Ernst Lengyel	Morning Session 9 AM - 12 PM
4/28/2025	Modulation of Tumor Microenvironment: Enhancing Immunogenicity and Counteracting Suppression	Section 38	Inhibiting NNMT in cancer-associated fibroblasts reduces immunosuppression	Ludwig Chicago	Janna Heide/Ernst Lengyel	Morning Session 9 AM - 12 PM
4/28/2025	Drug Combination Strategies for Cancer Treatment	Section 19	Navitoclax, a Bcl-2/xL inhibitor, and YM155, a survivin inhibitor, in combination with carboplatin effectively inhibit ovarian cancer tumor growth	Ludwig Chicago	Tejas Samantaray/Ernst Lengyel	Morning Session 9 AM - 12 PM
4/28/2025	Interplay between Immune System and Radio-, Chemo- and Targeted Therapies 1	Section 35	Combined anti-CSF-1R and anti-TIM-3 overcome immune-mediated mechanisms of PARP inhibitor (PARPi) resistance in BRCA1-associated triple negative breast cancer	Ludwig Harvard	Adam Nelson/Jennifer Guerriero	Morning Session 9 AM - 12 PM
4/28/2025	Cancer Evolution In Response to Therapy	Section 2	Chemotherapy enriches one of two pre-existing coordinated cellular programs characterized by inflammatory and stress pathways in high grade serous ovarian cancer	Ludwig Harvard	Nomeda Girnius/Joan Brugge	Morning Session 9 AM - 12 PM
4/28/2025	Novel Drug Resistance Mechanisms	Section 22	Fumarylacetoacetate hydrolase (FAH) stimulates resistance to CDK4/6 inhibitors in hormone receptor-positive breast cancer via a novel non-canonical function	Ludwig Harvard	Jenny Hogstrom/Gerburg Wulf	Evening Session 2-5 PM
4/28/2025	Aging and Senescence in the Tumor Microenvironment	Section 2	Cell populations in human breast cancers are molecularly and biologically distinct with age	Ludwig Harvard	Adrienne Parsons/Peter van Galen	Evening Session 2-5 PM
4/29/2025	Pediatric Cancer Models	Section 5	Development of immunocomplex pediatric tumor organoids for onco-immunotherapy research	Ludwig Stanford	Naiara Martinez Velez/Crystal Mackall	Morning Session 9 AM - 12 PM
4/29/2025	Liquid Biopsy: Circulating Nucleic Acids 2	Section 29	CANARY-TF: an improved copy number and tumor fraction estimator for liquid biopsy applications	Ludwig Stanford	Diego Almanza/Maximilian Diehn	Morning Session 9 AM - 12 PM

4/29/2025	Angiogenesis	Section 1	BNIP3-dependent muscle atrophy in cancer cachexia promotes PDAC progression	Ludwig Chicago	Alexandra Sophia Ware/Kay Macleod	Morning Session 9 AM - 12 PM
4/29/2025	Integrating Chromatin, Oncogenes, DNA Repair, and Biomarkers for Therapeutic Advancements	Section 11	PARP1 and EZH2 independently limit 5'-3' end resection to promote rapid DNA repair after radiation	Ludwig Chicago	Elena Efimova/Stephen Kron	Morning Session 9 AM - 12 PM
4/29/2025	Metabolic Pathways	Section 13	Regulation of metabolic programming in esophageal cancer by transcription factor p63	Ludwig MIT	Niamh McNamee/Matthew Vander Heiden	Morning Session 9 AM - 12 PM
4/29/2025	Metabolic Pathways	Section 13	Cancer cells exhibit novel metabolic vulnerabilities when exposed to low lipid environments	Ludwig MIT	Diya Ramesh/Matthew Vander Heiden	Morning Session 9 AM - 12 PM
4/29/2025	Kinases/Phosphatases, Ubiquitin, and Ubiquitin-like Proteins	Section 12	The causes and consequences of off-target activation of the GCN2-eIF2a-ATF4 axis in cancer therapy	Ludwig MIT	C. Ryland III/Matthew Vander Heiden	Morning Session 9 AM - 12 PM
4/29/2025	Liquid Biopsy: Circulating Nucleic Acids 2	Section 29	Enhancing circulating tumor DNA recovery and liquid biopsy sensitivity with precision liposomal priming agents	Ludwig MIT	Kasturi Chakraborty/Sangeeta Bhatia	Morning Session 9 AM - 12 PM
4/29/2025	Cancer Cell Heterogeneity, Evolution, and Trajectory Profiling	Section 3	Comprehensive analysis of somatic mutagenesis in normal tissues across 19,643 samples reveals insights into clonal evolution and tumorigenesis	Ludwig Harvard	Leonie Stockschläder/Chris Sander	Morning Session 9 AM - 12 PM
4/29/2025	Late-Breaking Research: Clinical Research 2 / Endocrinology	Late-Breaking Poster Session - Section 51	A transcriptomic signature predicts mortality risk and immune checkpoint inhibitor response beyond molecular and morphological features in lung adenocarcinoma from never smokers	Ludwig Chicago	Wei Zhao/Lixing Yang	Morning Session 9 AM - 12 PM
4/29/2025	Late-Breaking Research: Clinical Research 2 / Endocrinology	Late-Breaking Poster Session - Section 51	Novel performance quantification of MCED testing to aid clinical decisions: Analysis of a sequential reflex blood-based methylated ctDNA test	Ludwig Harvard	Hutan Ashrafian/Franziska Michor	Morning Session 9 AM - 12 PM
4/29/2025	Reversal of Drug Resistance 2	Section 23	SIRT5 promotes chemoresistance through metabolic rewiring for nucleotide replenishing in refractory triple negative breast cancer	Ludwig Harvard	Zuen Ren/Marcia Haigis, Leif Ellisen	Morning Session 9 AM - 12 PM
4/29/2025	Phase II and Phase III Clinical Trials in Progress	Section 51	Tagraxofusp plus venetoclax and azacitidine in patients ineligible for intensive chemotherapy with previously untreated CD123+ acute myeloid leukemia: A phase 2 multicenter trial	Ludwig Harvard	Alessandra Tosolini/Andrew Lane	Evening Session 2-5 PM
4/29/2025	Phase II Clinical Trials 2	Section 50	Fibroblast growth factor receptor (FGFR) inhibition demonstrates anti-tumor activity in succinate dehydrogenase deficient gastrointestinal stromal tumor (SDHd GIST)	Ludwig Harvard	Priscilla Merriam/Bradley Bernstein	Evening Session 2-5 PM
4/29/2025	A Role for the Tumor Microenvironment in Progression	Section 1	Decoding tumor intrinsic and stroma-related drug resistance in EGFR mutant NSCLC	Ludwig Harvard	Radhika Koranne/Aaron Hata	Evening Session 2-5 PM

4/29/2025	Drug Resistance in Molecular Targeted Therapies 4	Section 18	Single-cell and spatial approaches of identifying targets in endocrine therapy-resistant breast cancer	Ludwig Chicago	Svetlana Semina/Geoffrey Greene	Evening Session 2-5 PM
4/29/2025	Development of Chemopreventive Agents and Preclinical Models	Section 48	Zeaxanthin augments CD8+ effector T cell function by enhancing TCR stimulation	Ludwig Chicago	Freya Zhang/Chuan He	Evening Session 2-5 PM
4/29/2025	Antibodies 3: Multi-Target Checkpoint Inhibitors and Immune Activators	Section 37	PLT012, a humanized CD36-blocking antibody, is effective for unleashing anti-tumor immunity and against liver metastasis	Ludwig Lausanne	Yi-Ru Yu/Ping-Chih Ho	Evening Session 2-5 PM
4/29/2025	CAR Therapies: Emerging Approaches and Combinations	Section 38	Generation of multi-specific CAR T cells using a novel single-marker selection platform to target medulloblastoma heterogeneity	Ludwig Stanford	Diren Usta/Crystal Mackall	Evening Session 2-5 PM
4/30/2025	Identification of New Cancer Vulnerabilities Through Convergence Science	Section 45	Germline-p53-mutant adrenocortical carcinoma is a possible candidate for the novel use of arsenic trioxide as a first targeted anticancer therapy for Li-Fraumeni Syndrome	Ludwig Oxford	Neha Wali/Xin Lu	Morning Session 9 AM - 12 PM
4/30/2025	Metabolism and Signaling	Section 11	ATF4 is required for PanIN formation and PDAC via effects on nucleotide metabolism and suppression of p53 activity	Ludwig Chicago	Leah M. Ziolkowski/Kay Macleod	Morning Session 9 AM - 12 PM
4/30/2025	Identification of New Cancer Vulnerabilities Through Convergence Science	Section 45	Metabolic mechanisms underlying late recurrence in hormone receptor positive breast cancer	Ludwig Harvard	Bryce Ordway/Leif Ellisen	Morning Session 9 AM - 12 PM
4/30/2025	Vesicles in the Tumor Microenvironment	Section 6	HD-PTP modulates anti-tumor immunity via extracellular vesicles in triple-negative breast cancer	Ludwig Harvard	Chenxu Guo/Leif Ellisen	Morning Session 9 AM - 12 PM
4/30/2025	Liquid Biopsy: Circulating Nucleic Acids 4 / Predictive Biomarkers 1	Section 32	High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlates of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer	Ludwig Harvard	Alexander Gottlieb/Jennifer Guerriero	Morning Session 9 AM - 12 PM
4/30/2025	Drug Resistance in Molecular Targeted Therapies 5	Section 18	Elucidating mechanisms of cancer cell persistence to lorlatinib in ALK positive NSCLC	Ludwig Harvard	Toshio Fujino/Aaron Hata	Morning Session 9 AM - 12 PM
4/30/2025	Immune Monitoring / Clinical Correlates	Section 31	Unravelling temporal dynamics of GD2-CAR T cell therapy in H3K27M-mutant diffuse midline glioma through comprehensive single-cell and multi-omic profiling	Ludwig Stanford	Yiyun Chen/Crystal Mackall	Morning Session 9 AM - 12 PM